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Interferons (IFNs) exert their anti-viral effects by
inducing the expression of hundreds of IFN-stimu-
lated genes (ISGs). The activity of known ISGs is
insufficient to account for the antiretroviral effects
of IFN, suggesting that ISGs with antiretroviral ac-
tivity are yet to be described. We constructed an
arrayed library of ISGs from rhesus macaques and
tested the ability of hundreds of individual macaque
and human ISGs to inhibit early and late replication
steps for 11members of the retroviridae from various
host species. These screens uncovered numerous
ISGs with antiretroviral activity at both the early and
late stages of virus replication. Detailed analyses of
two antiretroviral ISGs indicate that indoleamine
2,3-dioxygenase 1 (IDO1) can inhibit retroviral repli-
cation by metabolite depletion while tripartite motif-
56 (TRIM56) accentuates ISG induction by IFNa and
inhibits the expression of late HIV-1 genes. Overall,
these studies reveal numerous host proteins that
mediate the antiretroviral activity of IFNs.
INTRODUCTION
Interferons (IFNs) are a component of an early response to
invading pathogens and induce the expression of hundreds of
IFN-stimulated genes (ISGs) (Schoggins et al., 2011; Stetson
andMedzhitov, 2006). The IFN response can ameliorate viral dis-
ease by facilitating clearance of acute infections, or by reducing
the volume of chronic virus replication. Additionally, a genetic
barrier imposed by species-dependent variation in antiviral
ISGs can prevent interspecies transmission of viruses.
Retroviruses are a diverse family that includes human and
simian immunodeficiency viruses (HIV and SIV). Multiple obser-392 Cell Host & Microbe 20, 392–405, September 14, 2016 ª 2016 T
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mission, and pathogenesis. For example, an IFNa antagonist
can increase acute SIV replication and accelerate disease pro-
gression, while IFNa treatment can prevent SIV infection of
macaques (Sandler et al., 2014) and reduce HIV-1 viremia in
humans (Asmuth et al., 2010). Moreover, IFN-resistance may
be selected during HIV-1 transmission (Fenton-May et al., 2013).
Some proteins with direct antiretroviral activity, such as
APOBEC3 proteins, TRIM5a, tetherin, SAMHD1, ZAP, CNP,
Mov10, and Mx2 (Doyle et al., 2015; Hatziioannou and Bieniasz,
2011), are encoded by ISGs. Additionally, some ISGs, namely
TRIM5 and tetherin, can also exert antiviral effects by signaling
to induce other antiviral genes (Gala˜o et al., 2012; Pertel et al.,
2011). Thus, response to IFN includes directly antiviral proteins
and signal amplifiers that are induced by IFNs (Schoggins
et al., 2014; Stetson andMedzhitov, 2006). However, the activity
of known ISGs is insufficient to account for the antiretroviral
effect of type I IFN, suggesting that some ISGs with antiretroviral
activity are yet to be described.
Rapid evolution at host-pathogen interfaces means that ISG
evasion or antagonism strategies employed by viruses are often
only effective in the native host (reviewed in Doyle et al., 2015).
Therefore, antiviral protein activity is sometimes revealed by us-
ing viral mutants or non-native viral hosts. HIV-1, for example,
evades or antagonizes human APOBEC3, TRIM5a, and tetherin
but is fully sensitive to these proteins in non-hominid species
(Doyle et al., 2015). Species-dependent variation in antiretroviral
proteins can constitute a profound genetic barrier to interspecies
retroviral transmission. Accordingly, type I IFN is a significantly
more potent inhibitor of HIV-1 and SIV infection in cells of non-
native primates (Bitzegeio et al., 2013). Nevertheless, some
ISGs exert antiviral effects without evidence for evasion or
antagonism by the retroviral target (Doyle et al., 2015).
These concepts shaped our approach to reveal ISGs that
inhibit retroviridae. We describe an arrayed library of ISGs from
a non-human species (M. mulatta) and a series of screens in
which we tested the ability of hundreds of individual ISGs from
humans and macaques to inhibit the replication of elevenhe Authors. Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
different retroviruses. This approach revealed that IFN’s an-
tiretroviral activity is mediated by numerous candidate antiviral
factors. We also describe detailed studies of two ISGs (IDO1
and TRIM56) that were revealed by our screens to exhibit antire-
troviral activity.
RESULTS
ISG Expression Screening to Identify Genes That Inhibit
Retrovirus Replication
We first generated arrayed libraries of hundreds of ISGs in
mammalian expression and lentiviral vectors and measured
the impact of each ISG on retroviral replication. To expand the
utility of a human ISG library (Schoggins et al., 2011) that we pre-
viously used to identify pathogen sensors and antiviral effectors
(Dittmann et al., 2015; Schoggins et al., 2014; Wilson et al., 2012)
and capture the ability of nonhuman ISGs to inhibit retroviruses,
we constructed a library of ISGs from rhesus macaques
(M. mulatta). This arrayed library contained 344 cDNAs from
unique macaque ISGs as well as >90 additional ORFs that
captured some of the allelic and splicing-generated diversity of
macaque ISGs. Together, the two libraries include 488 different
ISGs with 252 genes represented by both human and macaque
variants (Figure 1A).
To identify human and macaque ISGs with antiretroviral activ-
ity, we carried out 25 screens of 11 different retroviruses (Table
S1). We conducted these screens in two different ways. First,
we used an HIV-1-based lentiviral vector (SCRPSY, Figure 1B)
to express each ISG along with TagRFP in target cells that
were then challenged with GFP-encoding retroviruses or retro-
viral vectors. Infection was then measured using two-color flow
cytometry. This ‘‘incoming screening’’ strategy (Figure 1C) iden-
tifies ISGs that inhibit steps in the retroviral life cycle prior to GFP
expression. Second, we co-transfected an ISG-expression
plasmid (pDEST40) with a plasmid(s) that generates retroviral
particles, then measured the yield of infectious virions by trans-
duction of a GFP reporter gene, or using a reporter cell line. This
‘‘production screening’’ strategy (Figure 1D) identifies genes that
inhibit the latter stages of the retroviral life cycle. For each ISG,
the fraction of infected, ISG/TagRFP-expressing cells (incoming
screens) or the yield of infectious virions (production screens)
was expressed as a percentage of the mean value across all
wells in a given screen (Figures 1E, 1F, 2A–2G, S1B–S1E, S2,
S3, and S4).
Many ISGs Are Capable of Inhibiting Retroviral
Replication
The screens identified numerous ISGs that were apparently
capable of inhibiting the retroviral life cycle. A number of
ISGs that were known to have antiretroviral activity, including
several APOBEC3 proteins, TRIM5, tetherin, MOV10, SAMHD1,
CNP, and Mx2, were identified in the appropriate incoming or
production screens (Figures 1, 2, S1, S2, and S3; Table S5),
suggesting that this approach is a powerful way to identify anti-
viral genes. Many additional ISGs whose expression conferred
either resistance to incoming retroviral infection or reduced the
production of infectious retroviral particles were identified.
Some ISGs appeared to be specific inhibitors of one or a few
retroviruses, while others were broadly inhibitory. As examples,OASL inhibited the production of infectious prototypic foamy
virus (PFV) virions, and ULK4 inhibited the production of feline
immunodeficiency virus (FIV), but OASL and ULK4 had no
activity against other retroviruses. Conversely, macaque
SLFN12 inhibited the production of all retroviruses (Figures 1,
2, S1, S2, and S3; Table S5). Overall, 60% of ISGs were
hits against a single retrovirus, and the remainder targeted mul-
tiple retroviruses. In general, a greater number of ISGs were
more potently inhibitory in production screens than in the
incoming screens. This finding may result from potentially
higher ISG protein levels associated with transient transfection,
or may be due to the greater number and complexity of events
associated with the late, as opposed to the early, steps of
retroviral replication. A number of ISGs appeared to exert anti-
retroviral activity in a species-dependent manner. For example,
human, but not macaque, ANGTPL1 inhibited SIVmac produc-
tion, while macaque, but not human, IRF2 inhibited HIV-1 infec-
tion in human MT4 cells (Figures S1E–S1F and S4; Table S5).
More than one-third of the ‘‘hits’’ were identified exclusively us-
ing our macaque ISG library (Table S5), but further work is
required to determine which of these candidates have genuine
species-dependent antiretroviral activity.
The use of lentiviral vectors in incoming screens enabled the
effect of ISGs to be determined in different cellular back-
grounds. We conducted incoming screens using human
CD4+ T cell (MT4) and human CD4+ monocyte (THP-1) cell
lines as targets for HIV-1, HIV-2, and SIVmac infection. Inter-
estingly, more ISGs were protective in THP-1 cells than in
MT4 cells, even though MT4 cells were more efficiently trans-
duced with the ISG-encoding vectors (Figures 1 and S1; Table
S2). Ten ISGs conferred >10-fold protection against infection
by at least one primate lentivirus in THP-1 cells but conferred
minimal or no protection in MT4 cells (Figures 1, S1, S2,
and S3). These genes (cGAS, RIPK2, TLR7, IRF7, TRIM5,
TRIM38, MYD88, IL1R, LGALS9, and IFI16) included ISGs
known to mediate pattern recognition and inflammatory
signaling. Thus, the differential protection conferred by certain
ISGs likely reflects the differential ability of THP-1 and MT4
cells to transduce signals.
While ISG screening experiments are a powerful way to iden-
tify candidate antiretroviral ISGs, they do not distinguish be-
tween genes that act directly on viruses from those that serve
a regulatory function. Overexpression screening can also lead
to inhibition resulting from unnatural perturbation of cell physi-
ology. ISGs that inhibit one or a few retroviruses are less likely
to exert their effects through regulatory or nonspecific mecha-
nisms. However, ISGs with broad activity (e.g., tetherin) can
also have important effects. Validation and characterization of
all the candidate antiretroviral ISGs identified herein would take
many years. We therefore adopted a targeted approach to iden-
tify ISGs that (1) act directly to inhibit viral replication or (2) act as
regulators of the antiviral state. Importantly, we sought to identify
ISGs that affected retrovirus replication at native expression
levels.
Some ISGs Inhibit Retroviral Replication by Activating
Type I IFN or ISG Expression
To help identify ISGs that inhibited retroviral infection by facili-
tating the induction of an antiviral state, we determined whichCell Host & Microbe 20, 392–405, September 14, 2016 393
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Figure 1. ISG Screening Strategies and Effects of ISGs on HIV-1 and HIV-2
(A) Diagrammatic representations of genes present in the ISG libraries
(B) Schematic representation of the pSCRPSY lentiviral vector. D, splice donor; A, splice acceptor. See Supplemental Experimental Procedures for details.
(C and D) Screening strategy to identify candidate genes that protect cells from incoming retroviral infection (B) or reduce infectious virion yield from infected
cells (C).
(E and F) Effect of ISGs in incoming screens with HIV-1 (D) and HIV-2 (E) in MT4 and THP-1 cells and in production screens with HIV-1 (D) and HIV-2 (E) in 293T
cells. Black data points, human ISGs; blue data points, macaque ISGs. Hits that appear twice represent variant transcripts. All values were normalized to the
screen average (100 a.u.).ISGs could stimulate expression of type I IFN or other ISGs. We
generated 293T and THP-1 cell lines that expressed reporter
genes driven by the human IFNb promoter or an IFN-stimulated
response element (ISRE). These cells were transduced with the394 Cell Host & Microbe 20, 392–405, September 14, 2016ISG libraries and reporter gene expression recorded (Figures
3A and 3B; Tables S3 and S4). The ISRE reporter screens were
analyzed soon after transduction to minimize potential indirect
effects of IFN induction.
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Figure 2. Effects of Human and Macaque ISGs on Diverse Retroviruses
(A–F) The effect of ISGs on lentiviruses, FIV (A) and EIAV (B); betaretroviruses, MPMV (C) and HERV-K (D); gammaretroviruses, MLV (E) and CERV2/MLV (F); and a
spumaretrovirus, PFV (G). Screen details are as in Figures 1E and 1F except that the indicated cell lines were used.
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Figure 3. Putatively Indirect and Direct Effects of ISGs on Incoming HIV-1 and HIV-2 Infection
(A) Activation of integrated IFNb promoter driven luciferase reporter genes in HEK293T and THP-1 cells following transduction with lentiviral vectors encoding
macaque and human ISGs.
(B) Activation of integrated ISRE-driven GFP reporter gene in HEK293T cells following transduction with lentiviral vectors encoding macaque and human ISGs.
(C andD) Infectious titers of HIV-1-GFP andHIV-2-GFP inMT4 cells (C) and THP-1 cells (D) transducedwith SCRPSY vectors expressing selected ISGs. Titers are
mean + SD.Multiple ISGs that stimulated ISRE or IFNb promoter activity
were identified using this approach. An example was TRIM38,
whose expression activated the IFNb promoter (Figure 3A; Ta-
bles S3 and S4). Both human and macaque variants of TRIM38
conferred substantial protection against infection with HIV-1,
HIV-2, and SIVmac when expressed in THP-1 cells (5- to
10-fold), but not in MT4 cells (Figures 1, S1, S2, and S3). These
findings suggest that TRIM38may participate in pattern recogni-
tion or signaling pathways that lead to type I IFN expression and
consequently to inhibition of retroviral infection. As such, this and
other proteins identified in this screen are worthy of further inves-
tigation as proteins that may regulate IFN expression.
Candidate Directly Acting Inhibitors of Incoming
Retroviral Infection
We next elected to pursue ISGs that were likely to directly inhibit
incoming HIV-1 or HIV-2 infection. From a list of ISGs that
conferred >2-fold protection in any incoming HIV-1 or HIV-2396 Cell Host & Microbe 20, 392–405, September 14, 2016screen, we selected genes that did not stimulate IFNb-promoter
or ISRE driven reporter expression (Figures 3A and 3B; Tables S3
and S4). Thereafter, we determined infectious titers of HIV-1 and
HIV-2 onMT4andTHP-1 cells expressing these ISGs (Figures 3C
and 3D). This analysis confirmed the activity of ISGs known to
inhibit incoming HIV-1 and HIV-2 infection (such as TRIM5 and
Mx2) aswell as a number of ISGs forwhich anti HIV-1 orHIV-2 ac-
tivity was not previously described (e.g., IDO1, BCL3, LGALS9,
and C5orf39) (Figures 3C and 3D). Despite our attempts to focus
this sub-screen on directly acting ISGs, several genes that only
conferred protection in THP-1 cells, such as cGAS, human
TRIM5, and TLRs 3 and 7, likely act by inducing an antiviral state,
even though they did not activate IFNb or ISRE reporters (Figures
3A and 3B). Nevertheless, one ISG that had anti-HIV-1 activity
only in THP-1 cells, CDKN1A, may exert its effect by decreasing
SAMHD1 phosphorylation (Pauls et al., 2014). Thus, certain ISGs
may exert antiretroviral activity, contingent on cofactors that are
expressed in a cell-type-dependent manner.
IDO1 Inhibits Retroviral Replication
Of the candidate directly acting, not previously reported, inhibi-
tors of incoming retrovirus infection (Figures 3C and 3D; Table
S5), we selected IDO1 for further investigation. IDO1 encodes
indoleamine 2,3-dioxygenase 1, which catalyzes the initial rate-
limiting step in the conversion of L-tryptophan (L-Trp) to kynure-
nine (Hayaishi, 1976). Although IDO1 expression is upregulated
by type I IFNs, the magnitude of its induction by IFNg is clearly
greater (Hassanain et al., 1993). Notably, IDO1 expression is pro-
foundly upregulated during HIV-1 infection (Favre et al., 2010).
IDO1 was active in incoming screens against a number of retro-
viruses but appeared most potent against HIV-2 (Figures 1F, 2,
S1, S2, and S3; Table S5). Interestingly, it reduced both the in-
tensity and the number of EGFP-positive cells (Figures 4A and
4B) and was effective in MT4 cells, but not THP-1 cells (that
were less efficiently transduced) (Figure 1).
We generated MT4 cells that inducibly expressed IDO1 (Bus-
nadiego et al., 2014) at levels similar to those in IFNg-treated
A549 cells (in which IFNg is known to stimulate IDO1 expression)
(Figure 4C). In single-cycle infection assays, IDO1 expression in
target cells inhibited incoming HIV-2 infection by5-fold but did
not inhibit HIV-1 infection (Figure 4D). However, in spreading
replication assays, IDO1 reduced the number of HIV-1-infected
cells by >10-fold for several days (Figure 4E). Correspondingly,
the yield of infectious HIV-1 or HIV-2 progeny virions, harvested
44 hr after infection, was reduced by 50- to 100-fold, by IDO1,
similar to the reduction conferred by rhTRIM5a over a single
replication cycle (Figure 4F). Western blot analyses revealed
that IDO1 caused a substantial reduction in HIV-1 Gag, Env,
and Nef protein levels, and a corresponding reduction in extra-
cellular particulate CA (Figures 4G and 4H). Thus, IDO1 appears
to act by inhibiting viral protein production, and its identification
in an incoming screen was the result of reduced reporter gene
expression.
IDO1-driven generation of kynurenine can have immune regu-
latory effects (Opitz et al., 2011) and deplete L-Trp (Pfefferkorn,
1984; Schmidt and Schultze, 2014). Single-cycle HIV-1 replica-
tion was inhibited when cells MT4 expressing inducible IDO1
were mixed with unmodified cells, even when <50% cells
expressed IDO1 (Figure 4I). This finding suggested that IDO1 in-
hibits HIV-1 through L-Trp catabolites or by L-Trp depletion,
rather than the direct action of the IDO1 protein. Moreover,
1-methyl-L-tryptophan (1-MT), a competitive inhibitor of IDO1
enzymatic activity, substantially reversed the anti-HIV-1 effect
of IDO1 (Figure 4J). Crucially, L-Trp supplementation fully
restored IDO1-inhibited HIV-1 Gag expression and infectious
particle generation (Figure 4K). In the absence of IDO1, treat-
ment with 1-MT or additional L-Trp had little influence on infec-
tious progeny virion yield (Figure S5A and S5B). Because L-Trp
supplementation should not prevent the formation of IDO1-spe-
cific catabolites, IDO1 appears to inhibit HIV-1 through L-Trp
depletion.
IDO1 Can Constitute a Major Component of
IFNg-Mediated Inhibition of HIV-1
We next considered whether endogenous IDO1 contributes to
the anti-HIV-1 activity of IFNg (Hammer et al., 1986). IDO1 is
induced in antigen-presenting cells (APCs) following HIV-1 infec-
tion in vivo or IFNg stimulation in vitro (Favre et al., 2010), butmost immortalized cell lines do not respond to IFNg in this
way. Therefore, we used A549 cells, which, unusually, exhibit
robust IDO1 induction following IFNg treatment (Figure 5A).
IFNg treatment of A549 cells conferred only 2- to 3-fold protec-
tion from incoming pseudotyped HIV-1 infection (Figure 5B). In
contrast, IFNg caused up to 100-fold reduction in HIV-1 infec-
tious virion yield from infected A549 cells in a single cycle of repli-
cation (Figure 5C). Addition of L-Trp or 1-MT increased the yield
of infectious HIV-1 from IFNg-treated A549 cells by 10-fold
(Figure 5D) but did not have this effect in the absence of IFNg
(Figure S4C). A similar L-Trp induced rescue of infectious virion
yield occurred with IFNg–treated TZM-bl cells, a commonly
used HIV-1 indicator cell line (Figures 5D–5F and S5D). Thus,
IDO1-induced nutrient (L-Trp) depletion is responsible for a
substantial fraction of the anti-HIV-1 activity of IFNg in A549
and TZM-bl cells.
TRIM56 Expression Inhibits HIV-1 Replication
As an alternative approach to identify ISGs that could mediate
the antiretroviral activity of IFNa, several genes that were hits
in outgoing HIV-1 screens (>3-fold inhibition) were tested for
their ability to inhibit spreading HIV-1 replication when stably
expressed in GHOSTX4 indicator cells. HIV-1 replication in
GHOSTX4 cells is resistant to inhibition by IFNa (our unpub-
lished data), so this strategy could, in principle, capture
ISGs that regulate the antiviral state, or directly inhibit late
HIV-1 replication steps. Most of the selected ISGs modestly
inhibited HIV-1 replication GHOSTX4 cells (Figures 6A and
6B), but one ISG, TRIM56, substantially delayed HIV-1 spread
(Figure 6A). TRIM56 has previously been reported to inhibit
the replication of some, but not all, RNA viruses through
mechanisms that are unclear (Liu et al., 2014; Wang et al.,
2011). In our screens, TRIM56 greatly inhibited the production
of infectious HIV-1 and HERV-K virions and exhibited weak
activity against HIV-2 in incoming screens (Figures 1E, 1F,
and 2D).
We confirmed the apparent specificity of the effect of TRIM56
by cotransfecting varying amounts of TRIM56 expression
plasmid with plasmids generating infectious HIV-1 or MLV parti-
cles. TRIM56 reduced the yield of infectious HIV-1 particles by
up to 50-fold (Figures S6A and S6B) but had little effect on
MLV particle yield (Figures S6C and S6D). Western blot analysis
revealed that TRIM56 reduced the levels of cell- and virion-asso-
ciated HIV-1 Gag but did not affect MLV Gag expression. Thus,
exogenous TRIM56 appeared to specifically inhibit HIV-1 gene
expression.
We next generated nine single-cell clones of GHOSTX4 cells
expressing TRIM56 at levels that were only modestly higher
than unmodified GHOSTX4 cells (Figure 6C) and significantly
lower than the transiently transfected 293T cells used in the co-
transfection and screening experiments (Figures S6A and S6C).
When the GHOSTX4-TRIM56 clones were challenged with
HIV-1, viral spread was significantly delayed (four clones) or
apparently abolished (five clones; Figures 6D and 6E). Despite
this dramatic inhibition of viral spread, approximately equivalent
numbers of control and TRIM56-expressing cells were infected
in the initial infection cycle (Figure 6D). This finding is consistent
with the notion that TRIM56 inhibits late rather than early steps of
HIV-1 replication (Figure 1E).Cell Host & Microbe 20, 392–405, September 14, 2016 397
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Figure 4. IDO1 Inhibits HIV-1 and HIV-2 Replication
(A andB) FACSplots (A) and quantitation ofmean fluorescence intensity (MFI, B) depicting GFP expression following standard or low-dose HIV-2-GFP infection of
MT4 cells transduced with vectors expressing no ISG or IDO1.
(C) Western blot (WB) analysis of IDO1 expression with or without induction by IFNg (A549 cells) or doxycycline (Dox) (MT4-IDO1 cells).
(D) Infectious titer of HIV-1-GFP (NHG) or HIV-2-GFP in target MT4 cells containing Dox-inducible IDO1, rhT5a, or TagRFP.
(E) HIV-1-GFP (NHG) replication in MT4 cells containing Dox inducible IDO1, rhesus TRIM5a (rhT5a), or TagRFP.
(F) Production of infectious HIV-1-GFP (NHG) or HIV-2 (VSV-G pseudotyped ROD10) during a single cycle of replication in MT4 cells containing Dox inducible
IDO1, rhT5a, or TagRFP. Where indicated (53), 5-fold higher input was used to negate the ‘‘incoming’’ effect.
(G) WB analysis of Gag expression in the same HIV-1 (NHG) infected cells as in (F).
(H) Infectious titer of HIV-1 produced andWB analysis of Gag, Env, and Nef expression in MT4 cells containing Dox-inducible IDO1 during a single cycle of HIV-1
(NL4.3) replication.
(I) Yield of infectious virions and cell lysate and particulate capsid during a single replication cycle of mixed (in the indicated ratios) unmodified MT4 cells andMT4
cells containing Dox-inducible IDO1.
(J and K) Effects of 1-MT (J) or L-Trp (K) on the yield of infectious HIV-1 particles and WB analysis of expression and release of viral Gag proteins during a single
cycle of HIV-1 replication in MT4 cells containing Dox-inducible IDO1. Titers are mean + SD.Western blot analysis of a single cycle of HIV-1 replication in
one GHOSTX4-TRIM56 cell clone (#2) revealed that the product
of an early HIV-1 gene (Nef) was not affected by TRIM56 (Fig-398 Cell Host & Microbe 20, 392–405, September 14, 2016ure 6F). Conversely, Gag and Env expression and the yield of
viral particles were significantly reduced in GHOSTX4-
TRIM56#2 cells (Figure 6F). The reduction in yield of HIV-1
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Figure 5. Endogenous IDO1 Inhibits HIV-1
(A) WB analysis of IDO1 expression in IFNg-treated
A549 cells.
(B) Titer of VSV-G pseudotyped replication
competent HIV-1-GFP (NHG) on A549 cells
following treatment with increasing doses of IFNg.
(C) The yield of infectious progeny virions from a
single cycle of HIV-1 replication in A549 cells
treated with increasing doses of IFNg.
(D) The yield of infectious progeny virions from a
single cycle of HIV-1 replication in A549 cells
treated with IFNg in the presence of 50 mg/ml L-Trp
(D and E) or 100 mg/ml 1-MT (D and F).
(E) WB analysis of IDO1 expression in IFNg-treated
TZM-bl cells.
(F) As in D using TZM-bl cells. Titers aremean + SD.particles as measured by quantitative western blotting or using
infectivity assays was similar (Figures 6G and S6E), indicating
that TRIM56 reduced the number but not the infectiousness of
virions generated by infected cells.
TRIM56-Induced Inhibition of HIV-1 Involves Multiple
Viral and Host Genes
To identify viral determinants of TRIM56 sensitivity, we passaged
HIV-1 in GHOSTX4-TRIM56 cells. Replication was eventually de-
tected in some GHOST-TRIM56 clones (Figure 6E), and virions
harvested from these cells were used to initiate an iterative pas-
sage series in GHOSTX4-TRIM56#2 cells (Figure 6H). After eight
passages, replication was only modestly delayed in GHOSTX4-
TRIM56#2 cells. Sequence analysis of a full-length molecular
clone of the adapted virus (termed HIV-1/TRIM56R) revealed
numerous mutations including a frameshift in Vif and missense
mutations in Gag, Pol, Vpr, Tat, Rev, and Env (Figure 6I). In
single-cycle replication experiments, the yield of WT HIV-1 vi-
rions was diminished in the TRIM56-expressing clones, while
HIV-1/TRIM56R yielded similar levels of virions from control
and TRIM56-expressing cells (Figure 6J).
Unlike WT HIV-1, the cloned HIV-1/TRIM56R virus replicated
robustly in GHOSTX4-TRIM56#2 cells (Figure 7A) and with
slightly faster kinetics than WT HIV-1 in unmodified GHOSTX4
cells. Analysis of chimeric proviruses containing either the 50 or
30 half of the HIV-1/TRIM56R genome (50R and 30R; Figure 6I)
suggested that TRIM56 resistance mapped to the 30R region
(Figure 7B). Further analysis of chimeric viruses containing ele-
ments from 30R indicated that the TRIM56 resistant phenotype
could not be mapped to a single determinant (our unpublished
data). Nevertheless, a single substitution in the HIV-1 Env gene
(T6421A, Env N67K) present in 30R enabled some level of replica-
tion in GHOSTX4-TRIM56 cells (Figure 7B). When the T6421A
mutation was combined with mutations in 50R (generatingCell Host & MicHIV-1 50R-6421), the HIV-1/TRIM56R virus
phenotype was reproduced. Attempts to
map determinants within 50R conferring
TRIM56 resistance upon HIV-1 50R-6421
again indicated that multiple determinants
in 50R contributed to the HIV-1/TRIM56R
phenotype (our unpublished data). Thus,
the ability of the HIV-1/TRIM56R virus toreplicate in GHOSTX4-TRIM56#2 cells was conferred by the
cumulative effect of multiple mutations and not governed by a
single viral gene.
To determine whether endogenous TRIM56 could inhibit
HIV-1 replication, we used CRISPR editing to disrupt TRIM56
in an MT4 cell clone that contains an HIV-1 LTR-driven GFP
gene (MT4/LTR-GFP). We generated four Cas9-expressing
MT4/LTR-GFP subclones in which TRIM56 was not perturbed,
and seven expressing Cas9 and TRIM56-targeted guide RNAs.
All control MT4/LTR-GFP clones expressed equivalent levels of
TRIM56, while the TRIM56 targeted clones expressed greatly
reduced or undetectable levels of TRIM56 (Figure 7C). HIV-1
replicated with nearly identical kinetics in each of the cell
clones (Figure 7D), indicating that they were equally permissive
and that endogenous TRIM56 does not inhibit HIV-1 replication
(Figure 7D). Strikingly, however, in the presence of IFNa, which
elevated the level of TRIM56 expression 2-fold (Figures S7A
and S7B), replication was inhibited to a far greater extent in
unedited clones compared to clones in which TRIM56 was
disrupted.
Because resistance to TRIM56 involved multiple viral genes,
and the antiviral effect of endogenous TRIM56 was evident
only upon IFNa treatment, it was possible that TRIM56 acted
by increasing the levels or effects of other antiviral proteins. Ami-
croarray analysis of the four control and sevevn TRIM56
knockout MT4 clones, focusing on the 120 most highly IFNa-in-
duced ISGs, revealed that, despite variation among individual
cell clones, basal ISG expression (i.e., in the absence of IFN)
was generally unaffected by TRIM56 (Figure 7F). In contrast,
following IFNa treatment, many ISGs were expressed at higher
levels in control than in TRIM56 knockout clones (Figure 7G).
These genes included several that were hits in our screens
(Figure 1C), as well as known antiretroviral genes, including
APOBEC3G, Mx2, MOV10, and IFITM3. Analysis of a larger setrobe 20, 392–405, September 14, 2016 399
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Figure 6. TRIM56 Overexpression Can Inhibit HIV-1 Replication
(A and B) HIV-1 replication in populations of GHOST cells transduced with lentiviral vectors (CCIB) expressing the indicated human (A) or macaque (B) ISGs.
(C) WB analysis of GHOST cell clones overexpressing TRIM56.
(D) Single round HIV-1 infection of GHOST cells transduced with empty vector (CCIB, filled symbol) or clones overexpressing TRIM56.
(E) Spreading replication of HIV-1 in GHOST cells transduced with empty vector (CCIB, red symbol) or the clones overexpressing TRIM56 described in (C).
(F) WB analysis of Gag, Nef, Env, and TRIM56 expression and particle release in GHOST vector and GHOST-TRIM56#2 cells during a single cycle of HIV-1
infection.
(G) The yield of infectious progeny virions from a single cycle of HIV-1 replication in GHOST-vector and GHOST-TRIM56#2 cells.
(legend continued on next page)
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of 500 ISGs (Figures S7C and S7D) confirmed that TRIM56
knockout reduced ISG expression following IFNa treatment.
Thus, TRIM56 likely enhances the antiretroviral activity of IFNa,
at least in part, by enhancing cellular responsiveness to this
cytokine.
DISCUSSION
Here we report the most comprehensive screen of ISGs yet un-
dertaken for antiviral activity against a given virus family. Previ-
ously, we conducted a narrowly focused incoming screen that
tested the ability of human ISGs to inhibit HIV-1 (Schoggins
et al., 2011). Notably, those results are generally consistent
with this study, with five of seven ISGs re-identified in this study.
However, in this study we identified many additional candidate
anti-retroviral genes, a large number of which have not previ-
ously been reported to have antiretroviral activity. In general,
our findings underscore the complexity of the interferon
response with respect to inhibition of retroviral replication and
suggest that the antiretroviral activity of type I IFN is mediated
and regulated through the action of many ISGs (Table S5).
Some ISGs appeared to act in a retrovirus-specific manner,
while others had broad activity (Table S5). We also found some
discrepancies in the antiretroviral activity between human and
macaque variants of ISGs, which may contribute to the spe-
cies-dependent barriers to retroviral replication that can be
erected by type I IFN treatment (Bitzegeio et al., 2013). However,
a caveat is that the screens were conducted in human cells, and
it is possible that some ISGsmay only function properly in cells of
species from which they originate. Clearly, some of the genes
identified herein act to enhance or modify signaling pathway
rather than as directly antiviral proteins, while others appear to
have direct antiviral activity. To characterize all of the candidate
antiretroviral genes identified herein would take many years.
Thus, we have focused on a small number of ISGs, as proof-
of-principle of the usefulness of this strategy. Expression
screens such as those reported herein are a powerful tool, but
have weaknesses, including the potential for overexpression ar-
tifacts. However, we emphasize the fact that endogenous levels
of two host factors we identify characterized herein can cause in-
hibition of retroviral replication. These two ISGs contribute to the
anti-HIV-1 activity of IFNs via completely different mechanisms.
One antiretroviral ISG identified in our screens was IDO1. The
observation that exogenous L-Trp can relieve inhibition by IDO1
and IFNg strongly suggests that IDO1 inhibits HIV-1 through
L-Trp depletion rather than through the generation of catabolites
such as kynurenine. Nutrient-depletion is a recognized anti-
pathogen strategy and similar effects of IDO1 have been noted
for other pathogens including measles virus and hepatitis B virus
(Mao et al., 2011; Obojes et al., 2005). Indeed, SAMHD1, an IFN-
inducible deoxynucleoside triphosphate (dNTP) triphosphohy-
drolase that is also active against HIV-1, acts by depleting
essential substrates required for retrovirus replication (Gold-
stone et al., 2011).(H) Adaptation of HIV-1 to GHOST-TRIM56#2 cells via spreading replication. At
passaged onto GHOST-vector and GHOST-TRIM56#2 cells.
(I) Schematic representation and sequence analysis of an HIV-1 clone (TRIM56R
(J)WB analysis of Gag expression and particle release in GHOST vector andGHOSA simple explanation for the effects of IDO1 is that L-Trp
depletion could inhibit HIV-1 by limiting the availability of L-Trp
for nascent viral protein synthesis. However, it is also true that
T cells can actively respond to L-Trp depletion by activating
GCN2 and mTOR signaling pathways (Cobbold et al., 2009;
Munn et al., 2005), which could potentially impact viral gene
expression. Importantly, it is plausible that L-Trp could be suffi-
ciently depleted in T cells in vivo to exert an antiretroviral effect.
IDO1 is expressed at very high levels in APCs in HIV-1-infected
patients (Favre et al., 2010), and abundant IDO1 is observed in
the lymph nodes of SIV-infected macaques (Estes et al., 2006).
Efficient local depletion of L-Trp by APCs could therefore inhibit
HIV-1 replication in neighboring CD4+ T cells. Notably, IDO1 is
sufficiently active during chronic HIV-1 infection that serum
L-Trp can be 50% lower than in healthy controls (reviewed in
Murray, 2003). To impact serum L-Trp levels, extreme local
depletion of L-Trp likely occurs in the microenvironments (i.e.,
lymphoid tissues) that support viral replication. Crucially, such
local depletion of L-Trp is observed in vivo. GCN2 is activated
by L-Trp depletion to levels around 20-fold lower than in normal
serum and this IDO-dependent GCN2 activation is readily
observed in vivo (Munn et al., 2005). Thus, tissue microenviron-
ments likely experience L-Trp depletion to an extent that could
suppress HIV-1 replication.
Although L-Trp depletion has antiviral effects, elevated IDO1
activity has additional consequences in chronic HIV-1 infection
(Murray, 2003; Schmidt and Schultze, 2014), as it suppresses
T cell responses and promotes tolerance (Friberg et al., 2002;
Munn et al., 1998; Sakurai et al., 2002). IDO1 activity has been
reported to skew CD4+ T cell differentiation to regulatory
T cells at the expense of Th17 cells, thereby exacerbating
CD4+ Th17 depletion, perhaps leading to increased microbial
translocation and systemic immune activation (Brenchley et al.,
2006; Favre et al., 2010). Thus, IDO1 activity could potentially
mediate inhibition of HIV-1 replication while simultaneously
promoting immunosuppression.
Our screens uncovered two antiretroviral TRIM proteins,
TRIM38 and TRIM56, that appear to act by regulating the estab-
lishment of an antiviral state. Other TRIM proteins can stimulate
cell responses to pathogens, including TRIM25, which induces
ubiquitination of RIG-I (Gack et al., 2007), and TRIM5, which
has been implicated in promoting inflammatory transcription
(Pertel et al., 2011). Overexpression screens have suggested
that other TRIM proteins have antiretroviral activity, through un-
known mechanisms (Uchil et al., 2008). While overexpressed
TRIM56 did not appear to function through IFNb or ISRE pro-
moter elements, endogenous TRIM56 both increased the
expression of many ISGs in response to IFNa and enhanced
the establishment of an anti-HIV-1 state. Moreover, modest
TRIM56 overexpression caused dramatic inhibition of HIV-1
replication. It is likely that these findings are causally related,
although we cannot exclude the possibility that these reflect
distinct activities of TRIM56, as the signaling and directly antiviral
activities of tetherin and TRIM5 are clearly separable functionseach discontinuity, virions harvested from the GHOST-TRIM56#2 cells were
) adapted to replicate in GHOST cells expressing TRIM56.
T-TRIM56 cells, during a single cycle of HIV-1 andHIV-1/TRIM56R replication.
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Figure 7. Multiple Viral Determinants and ISGs Underlie Inhibition of HIV-1 Replication by Endogenous TRIM56
(A and B) Spreading replication of HIV-1 andHIV-1/TRIM56R in GHOSTX4-vector andGHOSTX4-TRIM56#2 cells (A), or chimeric viruses constructed using HIV-1
and HIV-1/TRIM56R (B).
(C) WB analysis of TRIM56 expression in clones of MT4-LTR-GFP cells transduced with lentiviral vectors expressing Cas9 only or Cas9 plus one of two TRIM56-
targeted guide RNAs (CR1 or CR3).
(D and E) HIV-1 replication in the absence (D) or presence (E) of 25U/ml IFNa in clones of control (n = 4) or TRIM56 knockout (n = 7) MT4-LTR-GFP cells
described in (C).
(F and G) Microarray analysis of the expression levels (in a.u.) for the 120 genes most highly induced by 25U/ml IFNa in clones of control (n = 4) or TRIM56
knockout (n = 7) MT4-LTR-GFP cells described in (C) in the presence (G) or absence (F) of IFN.
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(Gala˜o et al., 2012; Pertel et al., 2011). Previously, TRIM56 has
been reported to inhibit the replication of several RNA viruses,
while other RNA viruses are unaffected (Liu et al., 2014; Wang
et al., 2011); it has also been reported to enhance cellular
responsiveness to TLR3 signaling by binding to TRIF (Shen
et al., 2012) and to enhance IFNb production in response to
dsDNA by binding to and ubiquitinating STING (Tsuchida et al.,
2010). Our data are not consistent with an important role for
STING-induced IFN expression as a key mediator of TRIM56 an-
tiretroviral activity, because anti-HIV-1 activity of overexpressed
TRIM56 was observed in cells that do not express STING and
cGAS, and endogenous TRIM56 only exerted anti-HIV-1 activity
and enhanced ISG expression following IFNa treatment. STING-
independent TRIM56 antiviral activity has also been reported for
influenza viruses (Liu et al., 2016). Further work will be required to
determine precisely how TRIM56 functions to inhibit HIV-1
replication and whether any previously described properties
are relevant to its antiretroviral activity.
The consequences of ISG expression (such as nutrient deple-
tion) are expected to have fitness costs for the host. However, if
those costs are temporary, and smaller than those imposed by
viral infection, then ISG expression is ultimately beneficial to
the host. Thus, these data highlight the need for caution when
contemplating therapeutic interventions designed to modulate
the consequences of HIV-1 infection.Multiple ISGs that are asso-
ciated with immune activation, illness, and disease progression
during chronic infection likely also mediate suppression of HIV-1
replication. While the antiretroviral activities of ISGs are unable
to tip thebalance in favorof thehostduringnaturalHIV-1 infection,
it is clear the IFNs can slow or ameliorate disease in HIV-1 and
other retroviral infections. The findings reported herein should
inform future efforts to understand the molecular basis by which
IFNs shape susceptibility to retroviral infection, disease progres-
sion, cross-species transmission, and retroviral emergence.EXPERIMENTAL PROCEDURES
Retroviruses and Cell Lines
All the common cell lines were maintained under standard culture conditions
as detailed in the Supplemental Experimental Procedures. MT4-LTR-GFP in-
dicator cells and IFNb1/ISRE reporter cell lines represent cell clones modified
using MLV-derived retroviral vectors. ISG-expressing MT4 and GHOSTX4 cell
lines were modified using lentiviral vectors. Limiting dilution was also used to
generate a panel of GHOSTX4 cells, modified to express TRIM56. Replication
competent proviral clones encoding GFP (PFV) or pseudotyped envelope
minus derivatives of HIV-1,-1 (NHG Denv), HIV-2 (HIV-2 Denv EGFP), SIVmac,
(SIVmac Dnef Denv EGFP), and SIVagmTAN (Dnef Denv EGFP) or multi-
plasmid vector systems for FIV, EIAV, HERV-K, MLV, and CERV-2 encoding
GFP were used as described previously (Busnadiego et al., 2014; Kane
et al., 2013). Intact proviral clones of HIV-1 (NL4-3) (M19921) and HIV-2
(ROD10), as well as GFP encoding (in place of nef) NHG, were used. Infectivity
and replication assays were performed as described previously (Busnadiego
et al., 2014; Kane et al., 2013) and as detailed in the Supplemental Experi-
mental Procedures and Table S1.
ISG Screens
Using the same criteria used to select human ISGs (Dittmann et al., 2015;
Schoggins et al., 2011), we attempted to clone 600 macaque ISGs using
RT-PCR of IFN-treated Macaca mulatta cell lines. The resulting macaque
and extended human ISG libraries were subcloned into the pSCRPSY vector
(Accession KT368137) and pcDNA-DEST40 using Gateway (Invitrogen) tech-
nology. ISG screens were conducted in a 96-well plate format using SCRPSYlentiviral transduced target cells (incoming screens, ISRE and IFNb promoter
screens) or through cotransfection of 293T cells with ISGs encoded by
pcDNA-DEST40 (outgoing screens) detailed in the Supplemental Experimental
Procedures and Table S1. For each ISG, the fraction of infected, ISG/TagRFP-
expressing cells (incoming screens) or the yield of infectious virions (produc-
tion screens) was expressed as a percentage of themean value across all wells
for the respective library in a given screen, except theMPMV incoming screen,
in which values are expressed as the mean value across each plate. ISGs that
affected SCRPSY lentiviral titers are shown in Figure S1A and Table S2.
CRISPR-Mediated TRIM56 Knockout
A derivative of the HIV-based retroviral vector lentiCRISPR Version 2 (Addg-
ene, Plasmid #52961) was constructed. MT4-LTR-GFP knockout cells were
derived by transduction with lentiCRISPRV2-based viruses and single-cell
clones transduced with TRIM56-targeting CR1 and CR3 vectors were derived
by limiting dilution.
Quantitative Western Blotting
Western blotting was performed as described previously (Busnadiego et al.,
2014; Kane et al., 2013) and detailed in the Supplemental Experimental
Procedures using cell lysates and material pelleted through 20% sucrose.
Antigens were visualized using secondary antibodies labeled with IRDye
800CW or IRDye 680RD (LI-COR Biosciences or Thermo Scientific) and the
relevant primary antibody and scanned using a Li-Cor Odyssey Scanner.
Microarray Analysis
Total RNAwas extracted, using the RNeasy PlusMini Kit (QIAGEN), fromMT4-
LTR-GFP cells, control subclones, and CRISPR knockout subclones that were
untreated or treated with 25 U/ml IFNa (Sigma) for 24 hr before harvest. cRNA
was prepared and probed using Human HT12 Expression Beadchip (Illumina),
containing 48,000 transcript probes, according to the manufacturer’s
instructions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, five tables, and Supple-
mental Experimental Procedures and can be found with this article at http://
dx.doi.org/10.1016/j.chom.2016.08.005.
AUTHOR CONTRIBUTIONS
Conceptualization, P.D.B.; Library Construction, S.J.W., M.A., and J.S.;
Screening, S.J.W., M.K., F.Z., M.A., and T.K.; IDO1, S.J.R.; TRIM56, T.M.Z.;
Resources, J.S. and C.M.R.; Writing – Original Draft, S.J.W. and P.D.B.;
Writing – Review & Editing, M.K., T.M.Z., S.J.R., F.Z., T.K., J.S., C.M.R.,
S.J.W., and P.D.B.; Funding Acquisition, P.D.B., S.J.W., M.K., J.S., and
C.M.R.; Supervision, P.D.B. and S.J.W.
ACKNOWLEDGMENTS
We thank Steven Soll for CERV2/MLV chimeric Gag-Pol, Nick J. Loman and
Shalini Yadav for assistance, and the Developmental Studies Hybridoma
Bank, University of Iowa, and NIH AIDS reagents program for antibodies.
This work was supported by grants from the NIH R3764003 (to P.D.B.),
1F32AI116263-01 (to M.K.), AI091707 (to J.S. and C.M.R.), and UK MRC
MR/K024752/1 (to S.J.W.). The content of this piece is solely the responsibility
of the authors and does not necessarily represent the official views of the Na-
tional Institutes of Health.
Received: April 25, 2016
Revised: July 5, 2016
Accepted: July 27, 2016
Published: September 14, 2016
REFERENCES
Asmuth, D.M., Murphy, R.L., Rosenkranz, S.L., Lertora, J.J., Kottilil, S.,
Cramer, Y., Chan, E.S., Schooley, R.T., Rinaldo, C.R., Thielman, N.,Cell Host & Microbe 20, 392–405, September 14, 2016 403
et al.; AIDS Clinical Trials Group A5192 Team (2010). Safety, tolerability,
and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a
in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis.
201, 1686–1696.
Bitzegeio, J., Sampias, M., Bieniasz, P.D., and Hatziioannou, T. (2013).
Adaptation to the interferon-induced antiviral state by human and simian
immunodeficiency viruses. J. Virol. 87, 3549–3560.
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S.,
Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006). Microbial
translocation is a cause of systemic immune activation in chronic HIV infection.
Nat. Med. 12, 1365–1371.
Busnadiego, I., Kane, M., Rihn, S.J., Preugschas, H.F., Hughes, J., Blanco-
Melo, D., Strouvelle, V.P., Zang, T.M., Willett, B.J., Boutell, C., et al. (2014).
Host and viral determinants of Mx2 antiretroviral activity. J. Virol. 88, 7738–
7752.
Cobbold, S.P., Adams, E., Farquhar, C.A., Nolan, K.F., Howie, D., Lui, K.O.,
Fairchild, P.J., Mellor, A.L., Ron, D., andWaldmann, H. (2009). Infectious toler-
ance via the consumption of essential amino acids and mTOR signaling. Proc.
Natl. Acad. Sci. USA 106, 12055–12060.
Dittmann, M., Hoffmann, H.H., Scull, M.A., Gilmore, R.H., Bell, K.L.,
Ciancanelli, M.,Wilson, S.J., Crotta, S., Yu, Y., Flatley, B., et al. (2015). A serpin
shapes the extracellular environment to prevent influenza A virus maturation.
Cell 160, 631–643.
Doyle, T., Goujon, C., and Malim, M.H. (2015). HIV-1 and interferons: who’s
interfering with whom? Nat. Rev. Microbiol. 13, 403–413.
Estes, J.D., Li, Q., Reynolds, M.R., Wietgrefe, S., Duan, L., Schacker, T.,
Picker, L.J.,Watkins, D.I., Lifson, J.D., Reilly, C., et al. (2006). Premature induc-
tion of an immunosuppressive regulatory T cell response during acute simian
immunodeficiency virus infection. J. Infect. Dis. 193, 703–712.
Favre, D., Mold, J., Hunt, P.W., Kanwar, B., Loke, P., Seu, L., Barbour, J.D.,
Lowe, M.M., Jayawardene, A., Aweeka, F., et al. (2010). Tryptophan catabo-
lism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulato-
ry T cells in HIV disease. Sci. Transl. Med. 2, 32ra36.
Fenton-May, A.E., Dibben, O., Emmerich, T., Ding, H., Pfafferott, K., Aasa-
Chapman, M.M., Pellegrino, P., Williams, I., Cohen, M.S., Gao, F., et al.
(2013). Relative resistance of HIV-1 founder viruses to control by interferon-
alpha. Retrovirology 10, 146.
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann,
M., Mellor, A.L., Munn, D.H., and Antonia, S.J. (2002). Indoleamine 2,3-dioxy-
genase contributes to tumor cell evasion of T cell-mediated rejection.
International journal of cancer Journal international du cancer 101, 151–155.
Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O.,
Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007). TRIM25 RING-finger E3
ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446,
916–920.
Gala˜o, R.P., Le Tortorec, A., Pickering, S., Kueck, T., and Neil, S.J. (2012).
Innate sensing of HIV-1 assembly by Tetherin induces NFkB-dependent proin-
flammatory responses. Cell Host Microbe 12, 633–644.
Goldstone, D.C., Ennis-Adeniran, V., Hedden, J.J., Groom, H.C., Rice, G.I.,
Christodoulou, E., Walker, P.A., Kelly, G., Haire, L.F., Yap, M.W., et al.
(2011). HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate
triphosphohydrolase. Nature 480, 379–382.
Hammer, S.M., Gillis, J.M., Groopman, J.E., and Rose, R.M. (1986). In vitro
modification of human immunodeficiency virus infection by granulocyte-
macrophage colony-stimulating factor and gamma interferon. Proc. Natl.
Acad. Sci. USA 83, 8734–8738.
Hassanain, H.H., Chon, S.Y., and Gupta, S.L. (1993). Differential regulation of
human indoleamine 2,3-dioxygenase gene expression by interferons-gamma
and -alpha. Analysis of the regulatory region of the gene and identification of an
interferon-gamma-inducible DNA-binding factor. J. Biol. Chem. 268, 5077–
5084.
Hatziioannou, T., and Bieniasz, P.D. (2011). Antiretroviral restriction factors.
Curr. Opin. Virol. 1, 526–532.404 Cell Host & Microbe 20, 392–405, September 14, 2016Hayaishi, O. (1976). Properties and function of indoleamine 2,3-dioxygenase.
J. Biochem. 79, 13P–21P.
Kane, M., Yadav, S.S., Bitzegeio, J., Kutluay, S.B., Zang, T., Wilson, S.J.,
Schoggins, J.W., Rice, C.M., Yamashita, M., Hatziioannou, T., and Bieniasz,
P.D. (2013). MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature
502, 563–566.
Liu, B., Li, N.L., Wang, J., Shi, P.Y., Wang, T., Miller, M.A., and Li, K. (2014).
Overlapping and distinct molecular determinants dictating the antiviral activ-
ities of TRIM56 against flaviviruses and coronavirus. J. Virol. 88, 13821–13835.
Liu, B., Li, N.L., Shen, Y., Bao, X., Fabrizio, T., Elbahesh, H., Webby, R.J., and
Li, K. (2016). The C-Terminal Tail of TRIM56 Dictates Antiviral Restriction of
Influenza A and B Viruses by Impeding Viral RNA Synthesis. J. Virol. 90,
4369–4382.
Mao, R., Zhang, J., Jiang, D., Cai, D., Levy, J.M., Cuconati, A., Block, T.M.,
Guo, J.T., andGuo, H. (2011). Indoleamine 2,3-dioxygenasemediates the anti-
viral effect of gamma interferon against hepatitis B virus in human hepatocyte-
derived cells. J. Virol. 85, 1048–1057.
Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B.,
Brown, C., and Mellor, A.L. (1998). Prevention of allogeneic fetal rejection by
tryptophan catabolism. Science 281, 1191–1193.
Munn, D.H., Sharma, M.D., Baban, B., Harding, H.P., Zhang, Y., Ron, D., and
Mellor, A.L. (2005). GCN2 kinase in T cells mediates proliferative arrest and
anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22,
633–642.
Murray, M.F. (2003). Tryptophan depletion and HIV infection: a metabolic link
to pathogenesis. Lancet Infect. Dis. 3, 644–652.
Obojes, K., Andres, O., Kim, K.S., Da¨ubener, W., and Schneider-Schaulies, J.
(2005). Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles
virus activity of gamma interferon. J. Virol. 79, 7768–7776.
Opitz, C.A., Litzenburger, U.M., Sahm, F., Ott, M., Tritschler, I., Trump, S.,
Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011). An endog-
enous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Nature 478, 197–203.
Pauls, E., Ruiz, A., Riveira-Mun˜oz, E., Permanyer, M., Badia, R., Clotet, B.,
Keppler, O.T., Ballana, E., and Este, J.A. (2014). p21 regulates the HIV-1 re-
striction factor SAMHD1. Proc. Natl. Acad. Sci. USA 111, E1322–E1324.
Pertel, T., Hausmann, S., Morger, D., Zu¨ger, S., Guerra, J., Lascano, J.,
Reinhard, C., Santoni, F.A., Uchil, P.D., Chatel, L., et al. (2011). TRIM5 is an
innate immune sensor for the retrovirus capsid lattice. Nature 472, 361–365.
Pfefferkorn, E.R. (1984). Interferon gamma blocks the growth of Toxoplasma
gondii in human fibroblasts by inducing the host cells to degrade tryptophan.
Proc. Natl. Acad. Sci. USA 81, 908–912.
Sakurai, K., Zou, J.P., Tschetter, J.R., Ward, J.M., and Shearer, G.M. (2002).
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoim-
mune encephalomyelitis. J. Neuroimmunol. 129, 186–196.
Sandler, N.G., Bosinger, S.E., Estes, J.D., Zhu, R.T., Tharp, G.K., Boritz, E.,
Levin, D., Wijeyesinghe, S., Makamdop, K.N., del Prete, G.Q., et al. (2014).
Type I interferon responses in rhesus macaques prevent SIV infection and
slow disease progression. Nature 511, 601–605.
Schmidt, S.V., and Schultze, J.L. (2014). New Insights into IDO Biology in
Bacterial and Viral Infections. Front. Immunol. 5, 384.
Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz,
P., and Rice, C.M. (2011). A diverse range of gene products are effectors of the
type I interferon antiviral response. Nature 472, 481–485.
Schoggins, J.W., MacDuff, D.A., Imanaka, N., Gainey, M.D., Shrestha, B.,
Eitson, J.L., Mar, K.B., Richardson, R.B., Ratushny, A.V., Litvak, V., et al.
(2014). Pan-viral specificity of IFN-induced genes reveals new roles for
cGAS in innate immunity. Nature 505, 691–695.
Shen, Y., Li, N.L., Wang, J., Liu, B., Lester, S., and Li, K. (2012). TRIM56 is an
essential component of the TLR3 antiviral signaling pathway. J. Biol. Chem.
287, 36404–36413.
Stetson, D.B., and Medzhitov, R. (2006). Type I interferons in host defense.
Immunity 25, 373–381.
Tsuchida, T., Zou, J., Saitoh, T., Kumar, H., Abe, T., Matsuura, Y., Kawai,
T., and Akira, S. (2010). The ubiquitin ligase TRIM56 regulates innate im-
mune responses to intracellular double-stranded DNA. Immunity 33,
765–776.
Uchil, P.D., Quinlan, B.D., Chan, W.T., Luna, J.M., and Mothes, W. (2008).
TRIM E3 ligases interfere with early and late stages of the retroviral life cycle.
PLoS Pathog. 4, e16.Wang, J., Liu, B., Wang, N., Lee, Y.M., Liu, C., and Li, K. (2011). TRIM56 is a
virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infec-
tion. J. Virol. 85, 3733–3745.
Wilson, S.J., Schoggins, J.W., Zang, T., Kutluay, S.B., Jouvenet, N., Alim,
M.A., Bitzegeio, J., Rice, C.M., and Bieniasz, P.D. (2012). Inhibition of HIV-1
particle assembly by 20,30-cyclic-nucleotide 30-phosphodiesterase. Cell Host
Microbe 12, 585–597.Cell Host & Microbe 20, 392–405, September 14, 2016 405
